Clinical Trials in Huntsville, Alabama
43 recruiting
Showing 1–20 of 42 trials
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled279 locationsNCT07218380
Recruiting
Phase 3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim416 enrolled162 locationsNCT06151574
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled399 locationsNCT06531824
Recruiting
Phase 2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Chronic Kidney Disease
Boehringer Ingelheim416 enrolled153 locationsNCT06926660
Recruiting
Phase 3
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled842 locationsNCT06307652
Recruiting
Phase 2
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
Depressive Disorder, Major
Janssen Research & Development, LLC124 enrolled43 locationsNCT06785012
Recruiting
Phase 2
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Colorectal, Cancer
AbbVie140 enrolled41 locationsNCT07023289
Recruiting
Phase 2
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Major Depressive Disorder
Syndeio Biosciences, Inc164 enrolled34 locationsNCT06547489
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 1Phase 2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
AstraZeneca231 enrolled41 locationsNCT06749457
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled177 locationsNCT06029439
Recruiting
Not Applicable
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Heart Failure - NYHA II - IV
Boston Scientific Corporation850 enrolled18 locationsNCT07069738
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled353 locationsNCT06890598
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled564 locationsNCT07037459
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled229 locationsNCT07181109
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled917 locationsNCT06677060
Recruiting
Phase 3
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383